Commitment
Andarix Pharmaceuticals is developing and commercializing novel cancer therapies that are targeted to the patients most likely to respond. Tozaride, our lead product entering Phase 2 clinical trials, targets specific cancers at the molecular level, and its companion diagnostic identifies the patients with the corresponding molecular signature who are the best candidates for therapy.
Targeted Therapies
for Personalized Medicine
Peptide targeted radiotherapy is a promising new approach to cancer therapy and has been widely validated in clinical studies as well as in routine clinical use in Europe. Treating cancer with radiotherapy can achieve results not possible with conventional therapies because cancer cells are unable to evade the lethal damage caused by targeted radiation.
News & Events
Andarix Pharmaceuticals Announces Publication of Abstract Describing Lung Cancer Clinical Trial Results at ASCO 2017 Annual Meeting
Targeted Tozaride Drug Therapy for Small Cell Lung and neuroendocrine Cancer SOMERVILLE, Mass.— June 2, 2017 — Andarix Pharmaceuticals, a clinical stage company, announced today the publication of results of a phase1/2 clinical study in lung and neuroendocrine cancer patients. The abstract will be presented at the annual American Society of Clinical Oncology (ASCO)…
Read MoreAndarix Pharmaceuticals’ Targeted Therapy Reduced Tumor Size in Lung Cancer Study
Tozaride Demonstrates Significant Tumor Reduction in Clinical Study SOMERVILLE, Mass.—May 2, 2017— Andarix Pharmaceuticals, a clinical stage company, announced today the results of a phase1/2 clinical study in lung and neuroendocrine cancer patients. In an open label, single arm study, refractory lung cancer patients to standard of care therapy were identified by image analysis using…
Read MoreAndarix and Tulane University Collaborate to Further Research on Mediators of Cancer Cell Signaling
Andarix’ R&D expands to include Notch Influencing Molecules ANDARIX Pharmaceuticals, a clinical stage company developing targeted peptide therapy for cancers announced today that the Company has entered into an agreement with Tulane University, an institution at the forefront of modern medical innovation, to license the technology and intellectual property concerning Notch Influencing Molecules. The…
Read More